Key Speakers
• Eric Claessens, Director of Bulk Technologies, GlaxoSmithKline Biologicals
• David McIntosh, Medical Director, Vaccines and Infectious Diseases, Wyeth
• Guido Grandi, Senior Project Leader, Novartis Vaccines and Diagnostics
• Jon H. Heinrichs, Senior Research Fellow, Vaccine Basic Research, Merck Research Laboratories
• James Merson, Vice President and Chief Scientific Officer, Vaccines Research Unit, Pfizer
• Alexander von Gabain, Chief Scientific Officer, Intercell
• Barry Buckland, Chief Executive Officer, BiologicB
• Andrew Baum, Managing Director Equity Research, Morgan Stanley
• Hélène Pora, Director, Vaccine Application Development, Pall Life Sciences
• Raf Lemmens, Global Fast Trak Leader, GE Healthcare Life Sciences
• Othmar Engelhardt, Principal Scientist, National Institute for Biological Standards and Control
• Jacqui Shea, General Manager, Oxford-Emergent Tuberculosis Consortium
• Pete Gagnon, Chief Scientific Officer, Validated Biosystems
• Bernd Eisele, Chief Executive Officer, Vakzine Projekt Management
• John Savopulos, Director, VacZine Analytics
• David Kirke, Associate Director, ERA Consulting
We stand poised for the second golden era of vaccines, born of new advances in fields from recombinant molecular biology, to mass spectrometry, and bioinformatics1. Allied with new advances in formulation and process development, the global market will see growth of over 300% between 2009and 20231,2.
With more targets, more investment and more opportunity than ever, vaccinology has become one of the most dynamic fields in biomedicine today. Progress in reverse vaccinology, immuno-informatics and disposable technologies are revolutionising R&D for infectious disease, paediatric and cancer therapies.
And, as demonstrated by Prevnar, Infanrix and Gardasil, the blockbuster model, far from being obsolete, is alive and kicking in an arena historically characterised by low margins.
The rise of developing economies and new markets in the Asia-Pacific regions are augmenting the financial promise shown by new paediatric and adult therapies, pointing to a bright future ahead.
By attending Visiongain’s Vaccine Research & Development conference, you will benefit from distilled, market-focussed intelligence on the future for this exciting sector, from outstanding speakers in key areas including:
• Economic analysis of future trends including opportunities, drivers and challenges
• The R&D pipeline: future impact of new technologies
• How reverse vaccinology produced the H1N1 vaccine
• Progress towards a paediatric and adult 13 valent pneumococcal vaccine
• Surface proteome analysis as a fast-track for development of a GAS vaccine
• Clinical results for a new subunit booster vaccine for tuberculosis
• Development of a recombinant booster for prostate cancer
• New needle-free delivery methods
• Implementation of disposable technology in manufacturing
• Revisiting old tools in vaccine development
• MDCK cell-based based production methods and scale-up design considerations in bio-pharmaceutical manufacturing
• Purification of virus particles and DNA plasmids with monoliths
• The role of neutralising and monoclonal antibodies
• Collaborative partnering with lesser-developed countries
• BRIC countries in vaccine production
1 Poland, G.A. (2007). Pharmacology, Vaccinomics, and the Second Golden Age of Vaccinology. Clinical Pharmacology & Therapeutics, 82 (6), pp. 623-626.
2 Visiongain (2008). The Global Vaccines Market 2008-2023.
